Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Children With Central Nervous System Leukemia

Allemani, 2018, Global surveillance of trends in cancer survival, 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries, Lancet, 391, 1023, 10.1016/S0140-6736(17)33326-3 Zhou, 2019, New attempts for central nervous infiltration of pediatric acute lymphoblastic leukemia, Cancer Metastasis Rev, 38, 657, 10.1007/s10555-019-09827-z Pui, 2008, Current management and challenges of malignant disease in the CNS in paediatric leukaemia, Lancet Oncol, 9, 257, 10.1016/S1470-2045(08)70070-6 Marwaha, 2010, Central nervous system involvement at presentation in childhood acute lymphoblastic leukemia: management experience and lessons, Leuk Lymphoma, 51, 261, 10.3109/10428190903470323 Aldoss, 2017, Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors, Leukemia, 31, 777, 10.1038/leu.2016.391 Weng, 2018, A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia, J Hematol Oncol, 11, 25, 10.1186/s13045-018-0572-x Wang, 2018, Extramedullary relapse of acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation treated by CAR T-cell therapy: a case report, Onco Targets Ther, 11, 6327, 10.2147/OTT.S164430 Rubinstein, 2020, Chimeric antigen receptor T-cell therapy in patients with neurologic comorbidities, Pediatr Blood Cancer, 67, e28199, 10.1002/pbc.28199 Jacoby, 2018, Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia, Am J Hematol, 93, 1485, 10.1002/ajh.25274 Pui, 2013, A 50-year journey to cure childhood acute lymphoblastic leukemia, Semin Hematol, 50, 185, 10.1053/j.seminhematol.2013.06.007 Mitchell, 2010, Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001, Leukemia, 24, 406, 10.1038/leu.2009.256 Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet, 385, 517, 10.1016/S0140-6736(14)61403-3 Rice, 2019, Chimeric antigen receptor T cell–related neurotoxicity: mechanisms, clinical presentation, and approach to treatment, Curr Treat Options Neurol, 21, 40, 10.1007/s11940-019-0580-3 Gust, 2017, Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells, Cancer Discov, 7, 1404, 10.1158/2159-8290.CD-17-0698 Rivera, 2020, CAR T-cell–associated neurotoxicity: current management and emerging treatment strategies, Crit Care Nurs Q, 43, 191, 10.1097/CNQ.0000000000000302 Taraseviciute, 2018, Chimeric antigen receptor T cell–mediated neurotoxicity in nonhuman primates, Cancer Discov, 8, 750, 10.1158/2159-8290.CD-17-1368 Neelapu, 2018, Chimeric antigen receptor T-cell therapy—assessment and management of toxicities, Nat Rev Clin Oncol, 15, 47, 10.1038/nrclinonc.2017.148 Santomasso, 2018, Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia, Cancer Discov, 8, 958, 10.1158/2159-8290.CD-17-1319 Park, 2018, Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia, N Engl J Med, 378, 449, 10.1056/NEJMoa1709919 Nair, 2019, Functional improvement of chimeric antigen receptor through intrinsic interleukin-15Ralpha signaling, Curr Gene Ther, 19, 40, 10.2174/1566523218666181116093857 Yan, 2019, Critical factors in chimeric antigen receptor–modified T-cell (CAR-T) therapy for solid tumors, Onco Targets Ther, 12, 193, 10.2147/OTT.S190336 Imber, 2020, Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy, Br J Haematol, 190, 45, 10.1111/bjh.16541 Sim, 2019, Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma, Int J Radiat Oncol Biol Phys, 105, 1012, 10.1016/j.ijrobp.2019.05.065 Chow, 2019, Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy, Am J Hematol, 94, E209, 10.1002/ajh.25505